New Drugs for Myeloma

New Drugs for Myeloma Paul G. Richardson, Constantine Mitsiades, Robert Schlossman, Nikhil Munshi, Kenneth Anderson Oncologist 2007; 12: 664-689 Author Information and Disclosures Target Audience: Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the impact of novel agents on the treatment paradigm for multiple myeloma. Explain the importance of combination regimens and in particular the ability to rechallenge patients with a combination of drugs that may each have been administered separately before. Describe the toxicity profiles of the agents being used with a on key side effects and discuss the potential value of these agents in special populations, such as those with renal failure. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jun. 29, 2007 Most Recent Review: Jun. 29, 2007* Most Recent Update: Jun. 29, 2007 Date Credit Expires: October 15, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.